{"schema_version":"secwatch.filing_event.v1","accession":"0001816590-26-000047","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2026-07-07T10:33:23+00:00","discovered_at":"2026-07-07T10:35:01.385067+00:00","generated_at":"2026-07-07T10:35:09.358989+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Compass Pathways reports positive 26-week Phase 3 COMP006 data for COMP360 in TRD; NDA on track for Q4 2026","bullets":["39% of 25 mg arm achieved ≥25% MADRS reduction at Week 6, maintained through Week 26.","Retreatment in Part B enhanced benefit: nearly 30% of responders at Week 6 later achieved remission.","Safety profile generally well-tolerated; SAEs similar across arms (6.3% vs 5.7%).","Rolling NDA submission with FDA on track for Q4 2026; launch anticipated H1 2027 subject to approval and DEA rescheduling.","COMP006 enrolled 581 participants with highly chronic TRD (average depressive episode >3 years)."],"urls":{"canonical":"https://secwatch.observer/filing/0001816590-26-000047","json":"https://secwatch.observer/filing/0001816590-26-000047.json","markdown":"https://secwatch.observer/filing/0001816590-26-000047.md","text":"https://secwatch.observer/filing/0001816590-26-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/0001816590-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T10:35:09.358989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}